Abstract

Use of a compound of Formula (I) in a nonaqueous battery electrolyte formulation wherein R1 is independently selected from the group consisting of CF3, CH2CF3 and CFHCF3:R2 is independently selected from the group consisting of H, F, CH3, CH2F, CH2CF3, CH2OR5 and OR5; R3 is an alkyl group, with the formula CnH2n+1−xFx; R4 is H or F; and R5 is an alkyl group substituted N with at least on fluorine substituent, with the proviso that when R1 is CH2CF3 or CFHCF3, R2 is H, F or OR5, wherein the compound C of Formula (I) is present in the electrolyte formulation in an amount of 95 wt. % or less. Use of a compound of Formula (I) in a nonaqueous battery electrolyte formulation wherein R1 is independently selected from the group consisting of CF3, CH2CF3 and CFHCF3:R2 is independently selected from the group consisting of H, F, CH3, CH2F, CH2CF3, CH2OR5 and OR5; R3 is an alkyl group, with the formula CnH2n+1−xFx; R4 is H or F; and R5 is an alkyl group substituted N with at least on fluorine substituent, with the proviso that when R1 is CH2CF3 or CFHCF3, R2 is H, F or OR5, wherein the compound C of Formula (I) is present in the electrolyte formulation in an amount of 95 wt. % or less.

IPC Classes  ?

• H01M 10/0567 - Liquid materials characterised by the additives
• H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodes; Lithium-ion batteries
• H01M 10/054 - Accumulators with insertion or intercalation of metals other than lithium, e.g. with magnesium or aluminium
• H01M 10/0569 - Liquid materials characterised by the solvents

Abstract

Use of a compound of Formula 1 in a nonaqueous battery electrolyte formulation (1) wherein each R1 to R4 is selected from the group consisting of F, Cl, H, CF3, and C1 to C6 alkyl which may be at least partially fluorinated, wherein at least one of R1 to R4 is or comprises F. Use of a compound of Formula 1 in a nonaqueous battery electrolyte formulation (1) wherein each R1 to R4 is selected from the group consisting of F, Cl, H, CF3, and C1 to C6 alkyl which may be at least partially fluorinated, wherein at least one of R1 to R4 is or comprises F.

IPC Classes  ?

• H01M 10/42 - Methods or arrangements for servicing or maintenance of secondary cells or secondary half-cells
• H01M 10/0569 - Liquid materials characterised by the solvents
• H01M 50/383 - Flame arresting or ignition-preventing means

Abstract

Use of a compound of Formula 1 in a nonaqueous battery electrolyte formulation: wherein R is H, F, CF3, alkyl or fluoroalkyl. Use of a compound of Formula 1 in a nonaqueous battery electrolyte formulation: wherein R is H, F, CF3, alkyl or fluoroalkyl.

IPC Classes  ?

• H01M 10/052 - Li-accumulators
• H01M 10/0569 - Liquid materials characterised by the solvents

Abstract

Use of a compound of Formula I in a nonaqueous battery electrolyte formulation (I) wherein W is independently selected from the group consisting of H, F, Cl, Br and I; Y is independently selected from the group consisting of F, Cl, Br and I; Z is independently selected from the group consisting of H, O(CW2)PCW3, (CW2)PCW3, OCY3, OCW3, polyalkyiene glycol and polyoiesfer; n is an integer from 1-1000; one of T1 and T2 is W, the other is (CY2)mCY3; and p is an integer from 0 to 9, Use of a compound of Formula I in a nonaqueous battery electrolyte formulation (I) wherein W is independently selected from the group consisting of H, F, Cl, Br and I; Y is independently selected from the group consisting of F, Cl, Br and I; Z is independently selected from the group consisting of H, O(CW2)PCW3, (CW2)PCW3, OCY3, OCW3, polyalkyiene glycol and polyoiesfer; n is an integer from 1-1000; one of T1 and T2 is W, the other is (CY2)mCY3; and p is an integer from 0 to 9,

IPC Classes  ?

• H01M 10/0567 - Liquid materials characterised by the additives
• H01M 10/0568 - Liquid materials characterised by the solutes
• H01M 10/0569 - Liquid materials characterised by the solvents
• H01M 10/42 - Methods or arrangements for servicing or maintenance of secondary cells or secondary half-cells

Abstract

A process for the production of 1,1-difluoroethane by the catalytic fluorination, in the vapour phase, of a composition comprising vinyl chloride with hydrogen fluoride, wherein the vinyl chloride is contacted with hydrogen fluoride, at temperatures between 100 and 500° C., in the presence of a catalyst comprising a one or more of chromia, alumina, carbon.

IPC Classes  ?

• C07C 17/087 - Preparation of halogenated hydrocarbons by addition of hydrogen halides to unsaturated halogenated hydrocarbons
• C07C 17/383 - Separation; Purification; Stabilisation; Use of additives by distillation
• C07C 19/08 - Acyclic saturated compounds containing halogen atoms containing fluorine
• B01J 23/26 - Chromium
• B01J 23/06 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of zinc, cadmium or mercury

Abstract

A pharmaceutical composition comprises a drug component. The drug component comprises at least one pharmaceutically acceptable salt of glycopyrrolate, beclomethasone diproprionate, and at least one long acting beta-2-agonist (LABA) selected from formoterol and the pharmaceutically acceptable salts thereof. The pharmaceutical composition further comprises a propellant component. The propellant component consists of one or more hydrofluorocarbon and hydrocarbon propellant compounds, at least 90 weight % of which is 1,1-difluoroethane (HFA-152a). The drug component is the sole drug component in the pharmaceutical composition. The pharmaceutical composition is in the form of a solution and optionally comprises ethanol, but is free of other polar solvents/co-solvents.

IPC Classes  ?

• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• A61K 47/58 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/4704 - 2-Quinolinones, e.g. carbostyril
• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• A61K 47/10 - Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• A61K 47/12 - Carboxylic acids; Salts or anhydrides thereof
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers

Abstract

A pharmaceutical composition comprises a drug component. The drug component comprises at least one pharmaceutically acceptable salt of glycopyrrolate, budesonide, and at least one long acting beta-2-agonist (LABA) selected from formoterol and the pharmaceutically acceptable salts thereof. The pharmaceutical composition further comprises a propellant component. The propellant component consists of one or more hydrofluorocarbon and hydrocarbon propellant compounds, at least 90 weight % of which is 1,1-difluoroethane (HFA-152a). The drug component is the sole drug component in the pharmaceutical composition. The pharmaceutical composition is in the form of a suspension and optionally comprises ethanol, but is free of other polar solvents/co-solvents.

IPC Classes  ?

• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• A61K 47/58 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/4704 - 2-Quinolinones, e.g. carbostyril
• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• A61K 47/10 - Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• A61K 47/12 - Carboxylic acids; Salts or anhydrides thereof
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers

Abstract

Use of a composition comprises a compound of Formula 1 and a compound of Formula 2 in a nonaqueous battery electrolyte formulation wherein R is a fluorinated alkyl group and X is selected from the group consisting of F, Cl, H, CF3, and C1 to C6 alkyl which may be at least partially fluorinated and the group OR can be cis- or trans- to any other group: wherein R and R′ are H, F, Cl, CF3, alkyl or fluoroalkyl.

IPC Classes  ?

• H01M 10/0568 - Liquid materials characterised by the solutes
• H01M 10/0567 - Liquid materials characterised by the additives
• H01M 10/0569 - Liquid materials characterised by the solvents
• H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodes; Lithium-ion batteries

Abstract

Use of a compound of Formula (1) in a nonaqueous battery electrolyte formulation: (Formula (1)) wherein R is H, F, Cl, CF3, alkylr fluoroalkyl. Use of a compound of Formula (1) in a nonaqueous battery electrolyte formulation: (Formula (1)) wherein R is H, F, Cl, CF3, alkylr fluoroalkyl.

IPC Classes  ?

• H01M 10/0568 - Liquid materials characterised by the solutes
• H01M 10/0567 - Liquid materials characterised by the additives
• H01M 10/0569 - Liquid materials characterised by the solvents

Abstract

Use of a compound of Formula 1 in a nonaqueous battery electrolyte formulation (1) wherein R is a fluorinated alkyl group and X is selected from the group consisting of F, Cl, H, CF3, and C1 to C6 alkyl which may be at least partially fluorinated and —OR group can be cis- or trans- to any other group X. Use of a compound of Formula 1 in a nonaqueous battery electrolyte formulation (1) wherein R is a fluorinated alkyl group and X is selected from the group consisting of F, Cl, H, CF3, and C1 to C6 alkyl which may be at least partially fluorinated and —OR group can be cis- or trans- to any other group X.

IPC Classes  ?

• H01M 10/42 - Methods or arrangements for servicing or maintenance of secondary cells or secondary half-cells
• H01M 10/0569 - Liquid materials characterised by the solvents
• H01M 10/0567 - Liquid materials characterised by the additives

Abstract

A composition comprises (i) from about 2 to about 50% by weight 1,1-difluoroethene (vinylidene fluoride, R-1132a), (ii) from about 2 to about 95% by weight difluoromethane (R-32), and (iii) 2,3,3,3-tetrafluoropropene (R-1234yf).

IPC Classes  ?

• C09K 5/04 - Materials undergoing a change of physical state when used the change of state being from liquid to vapour or vice-versa
• C09K 3/30 - Materials not provided for elsewhere for aerosols

Abstract

Use of a formulation comprising a metal ion and a compound of Formula 1 in a nonaqueous battery electrolyte formulation wherein R1, R2, R3, R4 are independently selected from the group comprising H, F, Cl, Br, I, CF3, alkyl, fluoroalkyl, haloalkyl and R5 is independently selected from the group CF3, alkyl, fluoroalkyl, perfiuoroalkyl, haloalkyl perfluorohaloalkyl. Use of a formulation comprising a metal ion and a compound of Formula 1 in a nonaqueous battery electrolyte formulation wherein R1, R2, R3, R4 are independently selected from the group comprising H, F, Cl, Br, I, CF3, alkyl, fluoroalkyl, haloalkyl and R5 is independently selected from the group CF3, alkyl, fluoroalkyl, perfiuoroalkyl, haloalkyl perfluorohaloalkyl.

IPC Classes  ?

• H01M 10/0567 - Liquid materials characterised by the additives
• H01M 10/0568 - Liquid materials characterised by the solutes
• H01M 10/0569 - Liquid materials characterised by the solvents
• H01M 4/38 - Selection of substances as active materials, active masses, active liquids of elements or alloys

Abstract

A fluorite synthetic stone comprises: (a) a glass matrix comprising Ca, Si and O, and having a predetermined weight ratio of Ca to Si; and (b) CaF2 crystals dispersed in the glass matrix at a concentration of at least about 70 wt.%. A method of making fluorite synthetic stones includes formulating a particulate mixture comprising: CaF2 crystals at a concentration of at least about 70 wt.%; and an excipient having a predetermined weight ratio of Ca to Si. Aggregates are prepared from the particulate mixture. The aggregates are heat treated to form a plurality of fluorite synthetic stones, where each synthetic stone comprises: a glass matrix comprising Ca, Si and O; and CaF2 crystals dispersed in the glass matrix at a concentration of at least about 70 wt.%.

IPC Classes  ?

• C21C 7/064 - Dephosphorising; Desulfurising
• C03C 1/02 - Pretreated ingredients
• C21C 7/00 - Treating molten ferrous alloys, e.g. steel, not covered by groups
• C03C 14/00 - Glass compositions containing a non-glass component, e.g. compositions containing fibres, filaments, whiskers, platelets, or the like, dispersed in a glass matrix

Abstract

2222 crystals dispersed in the glass matrix at a concentration of at least about 70 wt.%.

IPC Classes  ?

• C03C 14/00 - Glass compositions containing a non-glass component, e.g. compositions containing fibres, filaments, whiskers, platelets, or the like, dispersed in a glass matrix
• C04B 30/00 - Compositions for artificial stone, not containing binders
• C04B 14/00 - Use of inorganic materials as fillers, e.g. pigments, for mortars, concrete or artificial stone; Treatment of inorganic materials specially adapted to enhance their filling properties in mortars, concrete or artificial stone
• C21C 1/02 - Dephosphorising or desulfurising
• C03C 10/00 - Devitrified glass ceramics, i.e. glass ceramics having a crystalline phase dispersed in a glassy phase and constituting at least 50% by weight of the total composition
• C03C 10/16 - Halogen-containing crystalline phase
• C04B 32/00 - Artificial stone not provided for in other groups of this subclass
• C04B 22/12 - Acids or salts thereof containing halogen in the anion, e.g. calcium chloride
• C04B 28/26 - Silicates of the alkali metals
• C21C 7/064 - Dephosphorising; Desulfurising

Abstract

A coolant for cooling an electrical/electronic element by direct immersion cooling, comprising a partially fluorinated ether with the structure (of compound 1) wherein R1, R2, R3, R4 are independently selected from the group CF3, alkyl, fluoroalkyl, perfluoroalkyl, haloalkyl perfluorohaloalkyl. A coolant for cooling an electrical/electronic element by direct immersion cooling, comprising a partially fluorinated ether with the structure (of compound 1) wherein R1, R2, R3, R4 are independently selected from the group CF3, alkyl, fluoroalkyl, perfluoroalkyl, haloalkyl perfluorohaloalkyl.

IPC Classes  ?

• C09K 5/04 - Materials undergoing a change of physical state when used the change of state being from liquid to vapour or vice-versa

Abstract

A pharmaceutical composition is described. The composition comprises: (i) a drug component comprising at least one antiviral compound that is suitable for treating viruses that cause adverse effects in the lungs; and (ii) a propellant. The composition can be delivered to the lungs using a metered dose inhaler (MDI).

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
• A61K 47/06 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61K 47/40 - Cyclodextrins; Derivatives thereof

Abstract

The present invention relates to compounds according to formula (Ia) or formula (Ib); pOH, polyalkylene glycol and 15 polyolester; n is an integer from 2 to 49; m is an integer from 0 to 3; p is an integer from 0 to 9; the molecular weight average (Mw) is ≤5500; and the polydispersity index is ≤1.45; compositions comprising these compounds and methods for their production.

IPC Classes  ?

• C10M 107/38 - Lubricating compositions characterised by the base-material being a macromolecular compound containing halogen
• C08G 65/00 - Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
• C08G 65/26 - Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds
• C10M 171/00 - Lubricating compositions characterised by purely physical criteria, e.g. containing as base-material, thickener or additive, ingredients which are characterised exclusively by their numerically specified physical properties, i.e. containing ingredien
• C10N 20/00 - Specified physical properties of component of lubricating compositions
• C10N 20/02 - Viscosity; Viscosity index
• C10N 20/04 - Molecular weight; Molecular weight distribution

Abstract

The invention provides a composition comprising (a) carbon dioxide (R-744, C02); (b) difluoromethane (R-32); and (c)a third component selected from 1,1,1,2-tetrafluoroethane (R- 134a), trans- 1,3, 3, 3-tetrafluoropropene (R-1234ze(E)), 2,3,3,3-tetrafluoropropene (R-1234yf), 1,1,1,2,3,3,3-heptafluoropropane (R-227ea) and mixtures thereof.

IPC Classes  ?

• C09K 5/04 - Materials undergoing a change of physical state when used the change of state being from liquid to vapour or vice-versa
• F25B 9/00 - Compression machines, plants or systems, in which the refrigerant is air or other gas of low boiling point

Abstract

The invention provides a composition comprising carbon dioxide (CO2, R-744), difluoromethane (R-32) and trifluoroiodomethane (CF3I) and the use of such a composition as a working fluid in a heat transfer system, such as a refrigeration, heat pump or air-conditioning system.

IPC Classes  ?

• C09K 5/04 - Materials undergoing a change of physical state when used the change of state being from liquid to vapour or vice-versa

Abstract

According to the present invention, there is provided a composition carbon dioxide (CO2, R-744), difluoromethane (R-32) and 1,1-difluoroethylene (R-1132a).

IPC Classes  ?

• C09K 5/04 - Materials undergoing a change of physical state when used the change of state being from liquid to vapour or vice-versa

Abstract

The use as a refrigerant of a composition comprising 1,1-difiuoroethyiene in a liquid chiller system.

IPC Classes  ?

• C09K 5/04 - Materials undergoing a change of physical state when used the change of state being from liquid to vapour or vice-versa

Abstract

A composition comprising: (i) 1,1-difluoroethene (vinylidene fluoride, R-1132a); (ii) carbon dioxide (CO2, R-744); (iii) pentafluoroethane (R-125); and (iv) one or more of trifluoromethane (R-23) and hexafluoroethane (R-116).

IPC Classes  ?

• C09K 5/04 - Materials undergoing a change of physical state when used the change of state being from liquid to vapour or vice-versa
• B01D 11/02 - Solvent extraction of solids
• A62D 1/00 - Fire-extinguishing compositions; Use of chemical substances in extinguishing fires
• C11D 7/50 - Solvents
• G06Q 50/26 - Government or public services
• B01D 11/04 - Solvent extraction of solutions which are liquid

Abstract

A pharmaceutical composition is described. The chemically stable pharmaceutical composition comprises a drug component. The drug component consists of a) mometasone, mometasone furoate, or a combination thereof; and b) formoterol fumarate dihydrate. The chemically stable pharmaceutical composition also comprises a propellant component comprising at least 90 weight % 1,1-difluoroethane; and ethanol in an amount of from 0.5 to 10% by weight based on the total weight of the chemically stable pharmaceutical composition. The drug component comprises from 0.01 to 1.0 weight % of the total weight of the chemically stable pharmaceutical composition. The drug component is the sole drug component in the chemically stable pharmaceutical composition. The chemically stable pharmaceutical composition is in the form of a suspension and free of acid stabilizers. The chemically stable pharmaceutical composition is surfactant-free.

IPC Classes  ?

• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• A61K 47/10 - Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

5555.

IPC Classes  ?

• C01B 25/10 - Halides or oxyhalides of phosphorus
• C01B 7/07 - Purification
• B01D 69/10 - Supported membranes; Membrane supports
• B01D 71/00 - Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor

Abstract

A method of recovering a lithium salt from a lithium battery waste mass, comprising the steps of: (a) dissolving the lithium sail in the lithium battery waste mass in a weight of water equivalent to 100 to 0.1 times the weight of the lithium battery waste mass, either in a one-off treatment or successive treatments; (b) evaporating the aqueous solution to dryness; and (c) working up the dry residue with a solvent comprising water, a carbonate, or mixtures thereof.

IPC Classes  ?

• C22B 26/12 - Obtaining lithium

Abstract

A pharmaceutical composition is described. The chemically stable pharmaceutical composition comprises (i) a drug component consisting of mometasone, mometasone furoate, or a combination thereof, (ii) a propellant component comprising 1,1-difluoroethane (R-152a), and (iii) ethanol in an amount of from 0.5 to 10% by weight based on the total weight of the chemically stable pharmaceutical composition. The drug component comprises from 0.01 to 1.0 weight % of the total weight of the chemically stable pharmaceutical composition. At least 95 weight % of the propellant component is 1,1-difluoroethane (R-152a). The drug component is the sole drug component in the pharmaceutical composition. The chemically stable pharmaceutical composition is surfactant-free.

IPC Classes  ?

• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• A61K 47/10 - Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids

Abstract

A method of recovering a lithium salt from a lithium battery waste mass, comprising the steps of: (a) dissolving the lithium sail in the lithium battery waste mass in a weight of water equivalent to 100 to 0.1 times the weight of the lithium battery waste mass, either in a one-off treatment or successive treatments; (b) evaporating the aqueous solution to dryness; and (c) working up the dry residue with a solvent comprising water, a carbonate, or mixtures thereof.

IPC Classes  ?

• C22B 26/12 - Obtaining lithium
• H01M 10/54 - Reclaiming serviceable parts of waste accumulators

Abstract

Use of a compound of Formula (I) in a nonaqueous battery electrolyte formulation (1) wherein R is a fluorinated alkyl group and X is selected from the group consisting of F, Cl, H, CF3, and C1 to C6 alkyl which may be at least partially fluorinated and —OR group can be cis- or trans- to any other group X. Use of a compound of Formula (I) in a nonaqueous battery electrolyte formulation (1) wherein R is a fluorinated alkyl group and X is selected from the group consisting of F, Cl, H, CF3, and C1 to C6 alkyl which may be at least partially fluorinated and —OR group can be cis- or trans- to any other group X.

IPC Classes  ?

• H01M 10/0567 - Liquid materials characterised by the additives
• C07C 43/17 - Unsaturated ethers containing halogen
• C07C 41/08 - Preparation of ethers by addition of compounds to unsaturated compounds by addition of organic compounds only to carbon-to-carbon triple bonds
• H01M 10/0568 - Liquid materials characterised by the solutes
• H01M 10/0569 - Liquid materials characterised by the solvents
• H01M 10/42 - Methods or arrangements for servicing or maintenance of secondary cells or secondary half-cells
• H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodes; Lithium-ion batteries

Abstract

Use of a compound of Formula 1 in a non-aqueous battery electrolyte formulation: wherein: R is an optionally fluorinated alky group, conveniently C1-6; each Y is independently H or F. X is H; a halogen, conveniently F; or an alkyl or a fluoroalkyl, conveniently C1-6; each Z is independently a halogen, conveniently F; or H.

IPC Classes  ?

• H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodes; Lithium-ion batteries
• H01M 10/054 - Accumulators with insertion or intercalation of metals other than lithium, e.g. with magnesium or aluminium
• H01M 10/0567 - Liquid materials characterised by the additives
• H01M 10/0568 - Liquid materials characterised by the solutes
• H01M 10/0569 - Liquid materials characterised by the solvents
• H01G 11/60 - Liquid electrolytes characterised by the solvent
• H01G 11/62 - Liquid electrolytes characterised by the solute, e.g. salts, anions or cations therein
• H01G 11/64 - Liquid electrolytes characterised by additives
• C07C 253/30 - Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
• C07C 255/16 - Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound oxygen atoms bound to the same carbon atom of an acyclic carbon skeleton
• H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
• H01M 4/587 - Carbonaceous material, e.g. graphite-intercalation compounds or CFx for inserting or intercalating light metals

Abstract

1-61-61-6; each Z is independently a halogen, conveniently F; or H.

IPC Classes  ?

• H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodes; Lithium-ion batteries
• C07C 253/30 - Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
• C07C 255/16 - Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound oxygen atoms bound to the same carbon atom of an acyclic carbon skeleton
• H01M 10/054 - Accumulators with insertion or intercalation of metals other than lithium, e.g. with magnesium or aluminium
• H01M 10/0567 - Liquid materials characterised by the additives
• H01M 10/0568 - Liquid materials characterised by the solutes
• H01M 10/0569 - Liquid materials characterised by the solvents
• H01G 11/60 - Liquid electrolytes characterised by the solvent
• H01G 11/62 - Liquid electrolytes characterised by the solute, e.g. salts, anions or cations therein
• H01G 11/64 - Liquid electrolytes characterised by additives
• H01M 6/16 - Cells with non-aqueous electrolyte with organic electrolyte
• H01M 4/525 - Selection of substances as active materials, active masses, active liquids of inorganic oxides or hydroxides of nickel, cobalt or iron of mixed oxides or hydroxides containing iron, cobalt or nickel for inserting or intercalating light metals, e.g. LiNiO2, LiCoO2 or LiCoOxFy
• H01M 4/587 - Carbonaceous material, e.g. graphite-intercalation compounds or CFx for inserting or intercalating light metals

Abstract

3 is H.

IPC Classes  ?

• C07D 301/26 - Y being hydrogen
• C08G 65/22 - Cyclic ethers having at least one atom other than carbon and hydrogen outside the ring
• C10M 107/38 - Lubricating compositions characterised by the base-material being a macromolecular compound containing halogen
• C10N 40/30 - Refrigerator lubricant

Abstract

A method for at least partially draining an operating system, which contains a working fluid (comprising carbon dioxide (R744) and a halogenated hydrocarbon). The method comprises transferring the working fluid to a target container, from the operating system, wherein the working fluid is contacted with an absorptive bed.

IPC Classes  ?

• F25B 45/00 - Arrangements for charging or discharging refrigerant
• F25B 9/00 - Compression machines, plants or systems, in which the refrigerant is air or other gas of low boiling point

Abstract

A method of charging a container for use in a medication delivery apparatus wherein the propellant used comprises 1,1-difluoroethane (R-152a) is described.

IPC Classes  ?

• A61M 15/00 - Inhalators
• B65B 3/00 - Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans or jars
• B65B 31/00 - Packaging articles or materials under special atmospheric or gaseous conditions; Adding propellants to aerosol containers

Abstract

A process for the production of 1,1-difluoroethane by the catalytic fluorination, in the vapour phase, of a composition comprising vinyl chloride with hydrogen fluoride, wherein the vinyl chloride is contacted with hydrogen fluoride, at temperatures between 100 and 500°C, in the presence of a catalyst comprising a one or more of chromia, alumina, carbon.

IPC Classes  ?

• C07C 17/21 - Preparation of halogenated hydrocarbons by replacement by halogens of halogen atoms by other halogen atoms with simultaneous increase of the number of halogen atoms
• C07C 21/18 - Acyclic unsaturated compounds containing halogen atoms containing carbon-to-carbon double bonds containing fluorine

Abstract

A pharmaceutical composition is described. The composition comprises: (i) a drug component consisting of salmeterol xinafoate and fluticasone propionate. and (ii) a propellant component at least 90 wt % of which is 1,1-difluoroethane (HFA-152a). The drug component is the sole drug component in the pharmaceutical composition.

IPC Classes  ?

• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/12 - Aerosols; Foams
• A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

3166 alkyl which may be at least partially fluorinated and -OR group can be cis- or trans- to any other group X.

IPC Classes  ?

• H01M 10/0569 - Liquid materials characterised by the solvents
• H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodes; Lithium-ion batteries
• H01M 10/42 - Methods or arrangements for servicing or maintenance of secondary cells or secondary half-cells
• C07C 41/24 - Preparation of ethers by reactions not forming ether-oxygen bonds by elimination of halogen, e.g. elimination of HCl
• C07C 43/17 - Unsaturated ethers containing halogen
• H01M 10/0568 - Liquid materials characterised by the solutes

Abstract

31633, alkyl or fluoroalkyl.

IPC Classes  ?

• H01M 10/0569 - Liquid materials characterised by the solvents
• H01M 10/052 - Li-accumulators
• H01M 10/42 - Methods or arrangements for servicing or maintenance of secondary cells or secondary half-cells
• H01M 4/38 - Selection of substances as active materials, active masses, active liquids of elements or alloys
• H01M 10/0568 - Liquid materials characterised by the solutes

Abstract

3, alkyl, fluoroalkyl, haloalkyl with a fluorinating agent.

IPC Classes  ?

• C07C 29/64 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by simultaneous introduction of hydroxy groups and halogens
• C07B 39/00 - Halogenation
• C07C 29/62 - Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring by substitution of halogen atoms by other halogen atoms

Abstract

A pharmaceutical composition is described. The composition comprises a drug component consisting of at least one indacaterol compound selected from indacaterol and indacaterol maleate, and at least one pharmaceutically acceptable salt of glycopyrrolate; and a propellant component at least 90 weight % of which is 1,1-difluoroethane (HFA-152a).

IPC Classes  ?

• A61K 31/4704 - 2-Quinolinones, e.g. carbostyril
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

According to the present invention, there is provided a composition comprising 1,1-difluoroethylene (R-1132a), fluoromethane (R-32), 2,3,3,3-tetrafluoropropene (R-1234yf) and carbo dioxide (CO2, R-744). The invention also provides a composition R-1132a, R-32, R-1234yf and at least one compound selected from the group consisting of: pentafluoroethane (R-125), 1,1-difluoroethane (R-152a), 1,1,1,2-tetrafluoroethane (R-134a), trans-1,3,3,3-tetrafluoropropene (R-1234ze(E)) and 1,1,1,2,3,3,3-hepta-fluoropropane (R-227ea); optionally, the composition comprises at least one further compound selected from the group consisting of trifluoroethylene (R-1123), propane (R-290), propylene (R-1270), isobutane (R-600a) and carbon dioxide (CO2, R-744). The present invention also provides a composition comprising R-1132a, R-32 and R-1234yf.

IPC Classes  ?

• C09K 5/04 - Materials undergoing a change of physical state when used the change of state being from liquid to vapour or vice-versa
• C09K 3/30 - Materials not provided for elsewhere for aerosols
• C11D 7/50 - Solvents
• C11D 7/30 - Halogenated hydrocarbons
• C11D 7/24 - Hydrocarbons
• C11D 7/04 - Water-soluble compounds
• C10M 105/38 - Esters of polyhydroxy compounds
• F25B 45/00 - Arrangements for charging or discharging refrigerant
• B01D 11/02 - Solvent extraction of solids

Abstract

cb, HF, HCl and air; wherein the process is carried out with a co-feed of air.

IPC Classes  ?

• C07C 17/20 - Preparation of halogenated hydrocarbons by replacement by halogens of halogen atoms by other halogen atoms
• B01J 23/06 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of zinc, cadmium or mercury
• B01J 23/26 - Chromium
• C07C 17/25 - Preparation of halogenated hydrocarbons by splitting-off hydrogen halides from halogenated hydrocarbons
• C07C 19/08 - Acyclic saturated compounds containing halogen atoms containing fluorine
• C07C 21/18 - Acyclic unsaturated compounds containing halogen atoms containing carbon-to-carbon double bonds containing fluorine

Abstract

A coolant for cooling an electrical / electronic element by direct immersion cooling, comprising a partially fluorinated ether with the structure (of compound 1) wherein R1,R2, R3, R4333, alkyl, fluoroalkyl, perfluoroalkyl, haloalkyl perfluorohaloalkyl.

IPC Classes  ?

• C09K 5/04 - Materials undergoing a change of physical state when used the change of state being from liquid to vapour or vice-versa
• C09K 5/10 - Liquid materials
• G06F 1/20 - Cooling means
• H01L 23/473 - Arrangements for cooling, heating, ventilating or temperature compensation involving the transfer of heat by flowing fluids by flowing liquids
• H01M 10/656 - Means for temperature control structurally associated with the cells characterised by the type of heat-exchange fluid
• H01M 10/6567 - Liquids
• H01M 10/6569 - Fluids undergoing a liquid-gas phase change or transition, e.g. evaporation or condensation
• H05K 7/20 - Modifications to facilitate cooling, ventilating, or heating

Abstract

A coolant for cooling an electrical / electronic element by direct immersion cooling, comprising a partially fluorinated ether with the structure (of compound 1) wherein R1, R2, R3, R4 are independently selected from the group comprising H, F, Cl, Br, I, CF3, alkyl, fluoroalkyl, haloalkyl and R5 is independently selected from the group CF3, alkyl, fluoroalkyl, perfluoroalkyl, haloalkyl perfluorohaloalkyl.

IPC Classes  ?

• C09K 5/10 - Liquid materials
• H01M 10/625 - Vehicles
• H01M 10/6568 - Liquids characterised by flow circuits, e.g. loops, located externally to the cells or cell casings
• H01M 10/6569 - Fluids undergoing a liquid-gas phase change or transition, e.g. evaporation or condensation
• C09K 5/04 - Materials undergoing a change of physical state when used the change of state being from liquid to vapour or vice-versa
• H01L 23/473 - Arrangements for cooling, heating, ventilating or temperature compensation involving the transfer of heat by flowing fluids by flowing liquids

Abstract

Use of a formulation comprising a metal ion and a compound of Formula 1 in a nonaqueous battery electrolyte formulation wherein R1,R2, R3, R433, alkyl, fluoroalkyl, haloalkyl and R533, alkyl, fluoroalkyl, perfiuoroalkyl, haloalkyl perfluorohaloalkyl.

IPC Classes  ?

• H01G 11/60 - Liquid electrolytes characterised by the solvent
• H01G 11/64 - Liquid electrolytes characterised by additives

Abstract

A pharmaceutical composition is described. The composition comprises: (i) a drug component comprising at least one antiviral compound that is suitable for treating viruses that cause adverse effects in the lungs; and (ii) a propellant. The composition can be delivered to the lungs using a metered dose inhaler (MDI).

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 31/14 - Antivirals for RNA viruses
• A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom

Abstract

A method for activating a chromia-based catalyst for fluorination and/or hydrofluorination comprises the steps of: a) optionally drying the catalyst at a temperature of from 100° C. to 400° C.; b) treating the catalyst with a composition comprising HF at a temperature of from 100° C. to about 500° C.; c) treating the catalyst with a composition comprising an oxidant and optionally HF at a temperature of from about 100° C. to about 500° C.

IPC Classes  ?

• B01J 23/26 - Chromium
• B01J 23/06 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of zinc, cadmium or mercury
• B01J 37/06 - Washing
• B01J 37/14 - Oxidising with gases containing free oxygen
• B01J 35/10 - Solids characterised by their surface properties or porosity
• C07C 17/07 - Preparation of halogenated hydrocarbons by addition of hydrogen halides

Abstract

The present invention relates to compounds according to formula (Ia) or formula (Ib); W) is ≤5500; and the polydispersity index is ≤1.45; compositions comprising these compounds and methods for their production.

IPC Classes  ?

• C10M 107/38 - Lubricating compositions characterised by the base-material being a macromolecular compound containing halogen
• C08G 65/00 - Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
• C08G 65/26 - Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring from cyclic ethers and other compounds
• C10M 171/00 - Lubricating compositions characterised by purely physical criteria, e.g. containing as base-material, thickener or additive, ingredients which are characterised exclusively by their numerically specified physical properties, i.e. containing ingredien
• C10N 20/00 - Specified physical properties of component of lubricating compositions
• C10N 20/02 - Viscosity; Viscosity index
• C10N 20/04 - Molecular weight; Molecular weight distribution

Abstract

A pharmaceutical composition is described. The composition comprises: (i) a drug component comprising at least one umeclidinium compound selected from umeclidinium and the pharmaceutically acceptable salts thereof, at least one vilanterol compound selected from vilanterol and the pharmaceutically acceptable salts and esters thereof and at least one fluticasone compound selected from fluticasone and the pharmaceutically acceptable salts and esters thereof; and (ii) a propellant component comprising 1,1-difluoroethane (HFA-152a).

IPC Classes  ?

• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• A61K 9/12 - Aerosols; Foams
• A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine

Abstract

(b)(ii) dehydrohalogenating 253fb to produce 1243zf in a second reactor, wherein the reaction product comprising 253fb produced in step (a) has subjected to one or more purification steps before step (b). The present invention also provides an azeotropic or near-azeotropic composition comprising HF and 253fb.

IPC Classes  ?

• C07C 17/25 - Preparation of halogenated hydrocarbons by splitting-off hydrogen halides from halogenated hydrocarbons
• C07C 17/35 - Preparation of halogenated hydrocarbons by reactions not affecting the number of carbon or halogen atoms in the molecules
• C07C 17/07 - Preparation of halogenated hydrocarbons by addition of hydrogen halides
• C09K 5/04 - Materials undergoing a change of physical state when used the change of state being from liquid to vapour or vice-versa

Abstract

A method for preparing a partially fluorinated ester comprising acyl and alkoxy groups wherein the acyl group comprises a branched or linear fluorine containing C3-C8 group with one of the structures: (Formulae (I), (II)) wherein X and Y are independently selected from: —H, —CH3, —F, —Cl, —CH2F, —CF3—OCF3, —OCH2CF3, OCH2CF2CHF2 and —CH2CF3 (wherein both X and Y cannot be H) comprising reacting an unsaturated halocarbon: (Formula (III)) wherein A and B are independently selected from the group comprising —H, —CH3, —F, —Cl, —CH2F, —CF3, —OCF3, —OCH2CF3, OCH2CF2CHF2 and —CH2CF3 (wherein both A and B cannot be H) with carbon monoxide and an alcohol, in the presence of a catalyst methods. A method for preparing a partially fluorinated ester comprising acyl and alkoxy groups wherein the acyl group comprises a branched or linear fluorine containing C3-C8 group with one of the structures: (Formulae (I), (II)) wherein X and Y are independently selected from: —H, —CH3, —F, —Cl, —CH2F, —CF3—OCF3, —OCH2CF3, OCH2CF2CHF2 and —CH2CF3 (wherein both X and Y cannot be H) comprising reacting an unsaturated halocarbon: (Formula (III)) wherein A and B are independently selected from the group comprising —H, —CH3, —F, —Cl, —CH2F, —CF3, —OCF3, —OCH2CF3, OCH2CF2CHF2 and —CH2CF3 (wherein both A and B cannot be H) with carbon monoxide and an alcohol, in the presence of a catalyst methods.

IPC Classes  ?

• C07C 67/38 - Preparation of carboxylic acid esters by reaction with carbon monoxide or formates by addition to an unsaturated carbon-to-carbon bond
• C07C 69/63 - Halogen-containing esters of saturated acids
• C07C 69/708 - Ethers
• C07C 69/675 - Esters of carboxylic acids having esterified carboxyl groups bound to acyclic carbon atoms and having any of the groups OH, O-metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids of saturated hydroxy-carboxylic acids
• C10M 105/54 - Lubricating compositions characterised by the base-material being a non-macromolecular organic compound containing halogen containing carbon, hydrogen, halogen and oxygen
• C09K 5/08 - Materials not undergoing a change of physical state when used
• H01M 10/0569 - Liquid materials characterised by the solvents

Abstract

2, polyalkylene glycol and polyolester; n is an integer from 2 to 250; m is an integer from 0 to 3; and p is an integer from 0 to 9.

IPC Classes  ?

• C10M 171/00 - Lubricating compositions characterised by purely physical criteria, e.g. containing as base-material, thickener or additive, ingredients which are characterised exclusively by their numerically specified physical properties, i.e. containing ingredien
• C09K 5/04 - Materials undergoing a change of physical state when used the change of state being from liquid to vapour or vice-versa
• C10M 107/38 - Lubricating compositions characterised by the base-material being a macromolecular compound containing halogen
• C09K 21/02 - Inorganic materials
• C09K 21/08 - Organic materials containing halogen
• C09K 21/10 - Organic materials containing nitrogen
• C09K 21/12 - Organic materials containing phosphorus
• C09K 21/14 - Macromolecular materials
• C10N 10/06 - Groups 3 or 13
• C10N 10/10 - Groups 5 or 15
• C10N 20/02 - Viscosity; Viscosity index
• C10N 20/00 - Specified physical properties of component of lubricating compositions
• C10N 30/08 - Resistance to extreme temperature
• C10N 40/30 - Refrigerator lubricant

Abstract

A pharmaceutical composition is described. The composition may include a drug component and a propellant component. The drug component comprises at least one pharmaceutically acceptable salt of glycopyrrolate and at least one long acting beta-2-agonist (LABA) selected from formoterol and the pharmaceutically acceptable salts thereof. At least 90 weight % of the propellant component is 1,1-difluoroethane (HFA-152a).

IPC Classes  ?

• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• A61K 47/58 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/4704 - 2-Quinolinones, e.g. carbostyril
• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• A61K 47/10 - Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• A61K 47/12 - Carboxylic acids; Salts or anhydrides thereof
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers

Abstract

A composition comprising trifluoroiodomethane (CF3I) and 1,1-difluoroethylene (R-1132a) is described. The composition can also comprise additional compounds, such as at least one non-flammable compound selected from the group consisting of carbon dioxide (CO2; R-744), tetrafluoromethane (R-14), trifluoromethane (R-23) and perfluoroethane (R-116) or at least one additional compound of lower volatility than 1,1-difluoroethylene selected from the group consisting of 1,1,2-trifluoroethylene (R-1123), difluoromethane (R-32), propane (R-290), propylene (R-1270), fluoroethane (R-161), pentafluoroethane (R-125), 1,1,1,2-tetrafluoroethane (R-134a), 2,3,3,3-tetrafluopropene (R-1234yf), isobutane (R-600a), n-butane (R-600), trans-1,3,3,3-tetrafluopropene (R-1234ze(E)), 3,3,3-trifluoropropene (R-1243zf), 1,2,3,3,3-pentafluoropropene (R-1225ye), 1, 1,1,2,3,3,3-heptafluoropropane (R-227ea), 1,1- difluoroethane (R-152a), cis-1,3,3,3-tetrafluopropene (R-1234ze(Z)), 1-chloro-3,3,3-trifluoropropene (R-1233zd(E/Z)) and 1,1,1,4,4,4-hexafluoro-2-butene (R-1336mzz(E/Z)). The compositions have utility as refrigerants in vapour compression heat transfer systems.

IPC Classes  ?

• C09K 5/04 - Materials undergoing a change of physical state when used the change of state being from liquid to vapour or vice-versa
• C07B 63/04 - Use of additives
• C09K 3/30 - Materials not provided for elsewhere for aerosols
• C11D 7/30 - Halogenated hydrocarbons
• C11D 7/04 - Water-soluble compounds
• F02C 3/00 - Gas-turbine plants characterised by the use of combustion products as the working fluid
• B01D 11/02 - Solvent extraction of solids
• B01D 11/04 - Solvent extraction of solutions which are liquid
• C02F 1/26 - Treatment of water, waste water, or sewage by extraction

Abstract

2, R-744), and, optionally, 1,1,2-trifluoroethene (R-1123).

IPC Classes  ?

• C09K 5/04 - Materials undergoing a change of physical state when used the change of state being from liquid to vapour or vice-versa
• C09K 3/30 - Materials not provided for elsewhere for aerosols

Abstract

2, R-744), and, optionally, 1,1,2-trifluoroethene (R-1123).

IPC Classes  ?

• C09K 5/04 - Materials undergoing a change of physical state when used the change of state being from liquid to vapour or vice-versa
• C09K 3/30 - Materials not provided for elsewhere for aerosols

Abstract

2).

IPC Classes  ?

• C09K 5/04 - Materials undergoing a change of physical state when used the change of state being from liquid to vapour or vice-versa
• C11D 7/50 - Solvents
• C09K 3/30 - Materials not provided for elsewhere for aerosols
• F01K 23/08 - Plants characterised by more than one engine delivering power external to the plant, the engines being driven by different fluids the engine cycles being thermally coupled combustion heat from one cycle heating the fluid in another cycle with working fluid of one cycle heating the fluid in another cycle
• F01K 25/10 - Plants or engines characterised by use of special working fluids, not otherwise provided for; Plants operating in closed cycles and not otherwise provided for using special vapours the vapours being cold, e.g. ammonia, carbon dioxide, ether

Abstract

A pharmaceutical composition is described. The composition comprises: (i) a drug component comprising at least one tiotropium compound selected from tiotropium and the pharmaceutically acceptable derivatives thereof; and (ii) a propellant component comprising 1,1-difluoroethane (HFA-152a).

IPC Classes  ?

• A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/06 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers

Goods & Services

Fluorite and fluorine-based chemicals and materials; electrolyte chemicals and materials; chemicals and materials for use in battery electrolytes; chemicals and materials for use in batteries and battery components. Batteries; battery components; fuel cells; fuel cell components; batteries and fuel cells for electric vehicles; battery components and fuel cell components for electric vehicles.

Goods & Services

(1) Acidulated water for recharging batteries; anti-frothing solutions for batteries; anti-sulphurizing agents for batteries; battery electrolytes; chemical agents sold as an ingredient of alkaline batteries; chemicals for use in the manufacture of lithium ion batteries; electrolyte solutions consisting of vanadium, sulphuric acid and hydrochloric acid; fluorine; fluorspar compounds; liquids for removing sulfates from batteries; salts for galvanic batteries; unprocessed fluoropolymer resin for use in extrusion and molding; (2) Battery plates; battery separators; battery starter cables; battery starters; battery terminal connector clamps; battery terminals; car batteries; chargers for electric batteries for electric vehicles; electric accumulators for vehicles; electric batteries for powering electric vehicles; electric batteries for vehicles; ignition batteries; lead acid batteries; lithium batteries; rechargeable batteries for electric vehicles;

Goods & Services

Fluorite and fluorine-based chemicals and materials, namely, hydrofluoric acid, fluorinated ethers, fluorinated esters, fluorinated carbonates; electrolyte chemicals and materials, namely, electrolyte additives, electrolyte salts, electrolyte solvents; chemicals and materials for use in battery electrolytes, namely, electrolyte additives, electrolyte salts, electrolyte solvents; chemicals and materials for use in batteries and battery components, namely, electrolyte additives, electrolyte salts, electrolyte solvents Batteries; component parts of batteries, namely, vent caps; fuel cell components, namely, electrolytes; batteries and fuel cells for electric vehicles; battery components and fuel cell components for electric vehicle, namely, electrolytes

Abstract

A pharmaceutical composition is described. The composition may include a drug component and a propellant component. The drug component comprises at least one pharmaceutically acceptable salt of glycopyrrolate and at least one long acting beta-2-agonist (LABA) selected from formoterol and the pharmaceutically acceptable salts thereof. At least 90 weight % of the propellant component is 1,1-difluoroethane (HFA-152a).

IPC Classes  ?

• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• A61K 47/58 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/4704 - 2-Quinolinones, e.g. carbostyril
• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• A61K 47/10 - Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• A61K 47/12 - Carboxylic acids; Salts or anhydrides thereof
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers

Abstract

A pharmaceutical composition is described. The composition may include a drug component and a propellant component. The drug component comprises at least one pharmaceutically acceptable salt of glycopyrrolate, budesonide, and at least one long acting beta-2-agonist (LABA) selected from formoterol and the pharmaceutically acceptable salts thereof. The propellant component comprises 1,1-difluoroethane (HFA-152a).

IPC Classes  ?

• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• A61K 47/58 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/4704 - 2-Quinolinones, e.g. carbostyril
• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• A61K 47/10 - Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• A61K 47/12 - Carboxylic acids; Salts or anhydrides thereof
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers

Abstract

A pharmaceutical composition is described. The composition may include a drug component and a propellant component. The drug component comprises at least one pharmaceutically acceptable salt of glycopyrrolate, beclomethasone diproprionate, and at least one long acting beta-2-agonist (LABA) selected from formoterol and the pharmaceutically acceptable salts thereof. The propellant component comprises 1,1-difluoroethane (HFA-152a).

IPC Classes  ?

• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• A61K 47/58 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/4704 - 2-Quinolinones, e.g. carbostyril
• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• A61K 47/10 - Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• A61K 47/12 - Carboxylic acids; Salts or anhydrides thereof
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers

Abstract

Use as a refrigerant in a heat pump system in an electric vehicle of a composition is described. The composition comprises 1,1-difluoroethylene (R-1132a) and at least one fluorocarbon refrigerant compound selected from the group consisting of 2,3,3,3-tetrafluoropropene (R-1234yf), difluoromethane (R-32), 1,3,3,3-tetrafluoropropene (R-1234ze(E)) and 1,1-difluoroethane (R-152a).

IPC Classes  ?

• C09K 5/04 - Materials undergoing a change of physical state when used the change of state being from liquid to vapour or vice-versa
• C10M 107/34 - Polyoxyalkylenes
• B60H 1/00 - Heating, cooling or ventilating devices
• F25B 13/00 - Compression machines, plants or systems, with reversible cycle

Abstract

The invention provides a composition comprising carbon dioxide (C02, R-744), difluoromethane (R-32) and trifluoroiodomethane (CF3I) and the use of such a composition as a working fluid in a heat transfer system, such as a refrigeration, heat pump or air-conditioning system.

IPC Classes  ?

• C09K 5/04 - Materials undergoing a change of physical state when used the change of state being from liquid to vapour or vice-versa

Abstract

The use as a refrigerant of a composition comprising 1,1-difiuoroethyiene in a liquid chiller system.

IPC Classes  ?

• C09K 5/04 - Materials undergoing a change of physical state when used the change of state being from liquid to vapour or vice-versa

Abstract

The invention provides a composition comprising (a) carbon dioxide (R-744, C02); (b) difluoromethane (R-32); and (c)a third component selected from 1,1,1,2-tetrafluoroethane (R- 134a), trans- 1,3, 3, 3-tetrafluoropropene (R-1234ze(E)), 2,3,3,3-tetrafluoropropene (R-1234yf), 1,1,1,2,3,3,3-heptafluoropropane (R-227ea) and mixtures thereof.

IPC Classes  ?

• C09K 5/04 - Materials undergoing a change of physical state when used the change of state being from liquid to vapour or vice-versa

Abstract

The use as a refrigerant of a composition comprising 1,1-difiuoroethyiene in a liquid chiller system.

IPC Classes  ?

• C09K 5/04 - Materials undergoing a change of physical state when used the change of state being from liquid to vapour or vice-versa
• B60H 1/32 - Cooling devices

Abstract

22, R- 744), difluoromethane (R-32) and 1,1-difluoroethylene (R-1132a).

IPC Classes  ?

• C09K 5/04 - Materials undergoing a change of physical state when used the change of state being from liquid to vapour or vice-versa

Abstract

33I) and the use of such a composition as a working fluid in a heat transfer system, such as a refrigeration, heat pump or air-conditioning system.

IPC Classes  ?

• C09K 5/04 - Materials undergoing a change of physical state when used the change of state being from liquid to vapour or vice-versa

Abstract

According to the present invention, there is provided a composition carbon dioxide (CO2, R- 744), difluoromethane (R-32) and 1,1-difluoroethylene (R-1132a).

IPC Classes  ?

• C09K 5/04 - Materials undergoing a change of physical state when used the change of state being from liquid to vapour or vice-versa

Abstract

2transtrans- 1,3, 3, 3-tetrafluoropropene (R-1234ze(E)), 2,3,3,3-tetrafluoropropene (R-1234yf), 1,1,1,2,3,3,3-heptafluoropropane (R-227ea) and mixtures thereof.

IPC Classes  ?

• C09K 5/04 - Materials undergoing a change of physical state when used the change of state being from liquid to vapour or vice-versa

Abstract

A pharmaceutical composition is described. The composition comprises; (i) a drug component comprising salbutamol; and (ii) a propellant component comprising 1,1-difluoroethane (HFA-152a).

IPC Classes  ?

• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61K 47/06 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• A61K 47/10 - Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
• A61K 31/46 - 8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
• A61K 31/5386 - 1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
• A61M 15/00 - Inhalators
• A61J 1/14 - Containers specially adapted for medical or pharmaceutical purposes - Details; Accessories therefor

Abstract

2; R-744) and from 1 to 32 weight % difluoromethane (R-32) based on the total weight of the composition is described. Also described is the use of the refrigerant composition for providing heating and cooling and a refrigeration, air-conditioning or heat pump system comprising the refrigerant composition.

IPC Classes  ?

• C09K 5/04 - Materials undergoing a change of physical state when used the change of state being from liquid to vapour or vice-versa
• F25B 9/00 - Compression machines, plants or systems, in which the refrigerant is air or other gas of low boiling point
• F25B 30/02 - Heat pumps of the compression type

Abstract

The present disclosure provides compounds of formula (I), and preparation method thereof, 3; and Z is independently selected from the group consisting of H, F, Cl, Br and I. Such compounds may be utilised as lubricants, for example in heat transfer compositions.

IPC Classes  ?

• C07C 69/63 - Halogen-containing esters of saturated acids
• C09K 5/04 - Materials undergoing a change of physical state when used the change of state being from liquid to vapour or vice-versa
• C10M 171/00 - Lubricating compositions characterised by purely physical criteria, e.g. containing as base-material, thickener or additive, ingredients which are characterised exclusively by their numerically specified physical properties, i.e. containing ingredien
• C10M 131/12 - Acids; Salts or esters thereof
• C10N 10/10 - Groups 5 or 15
• C10N 20/00 - Specified physical properties of component of lubricating compositions
• C10N 30/08 - Resistance to extreme temperature
• C10N 40/30 - Refrigerator lubricant

Abstract

2P32P3332m3;3; and p is an integer from 0 to 9,

IPC Classes  ?

• H01M 10/052 - Li-accumulators
• H01M 10/0567 - Liquid materials characterised by the additives
• H01M 10/0568 - Liquid materials characterised by the solutes
• H01M 10/0569 - Liquid materials characterised by the solvents
• H01G 9/035 - Liquid electrolytes, e.g. impregnating materials
• H01G 11/64 - Liquid electrolytes characterised by additives

Abstract

Use of a compound of Formula 1 in a nonaqueous battery electrolyte formulation (1) wherein each R1to R43166 alkyl which may be at least partially fluorinated, wherein at least one of R1to R4 is or comprises F.

IPC Classes  ?

• H01M 10/0567 - Liquid materials characterised by the additives
• H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodes; Lithium-ion batteries
• H01M 10/42 - Methods or arrangements for servicing or maintenance of secondary cells or secondary half-cells
• C07D 301/03 - Synthesis of the oxirane ring by oxidation of unsaturated compounds, or of mixtures of unsaturated and saturated compounds
• C07D 301/12 - Synthesis of the oxirane ring by oxidation of unsaturated compounds, or of mixtures of unsaturated and saturated compounds with hydrogen peroxide or inorganic peroxides or peracids
• C07D 303/08 - Compounds containing oxirane rings with hydrocarbon radicals, substituted by halogen atoms, nitro radicals or nitroso radicals
• H01M 10/0568 - Liquid materials characterised by the solutes
• H01M 10/0569 - Liquid materials characterised by the solvents

Abstract

13233232232553n2n+1-xx451233255, wherein the compound of Formula (I) is present in the electrolyte formulation in an amount of 95 wt.% or less.

IPC Classes  ?

• H01M 10/0567 - Liquid materials characterised by the additives
• H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodes; Lithium-ion batteries
• H01M 10/42 - Methods or arrangements for servicing or maintenance of secondary cells or secondary half-cells
• H01M 10/0568 - Liquid materials characterised by the solutes
• H01M 10/0569 - Liquid materials characterised by the solvents

Abstract

33, alkyl or fluoroalkyl.

IPC Classes  ?

• H01M 10/052 - Li-accumulators
• H01M 10/0567 - Liquid materials characterised by the additives
• H01M 10/0568 - Liquid materials characterised by the solutes
• H01M 10/0569 - Liquid materials characterised by the solvents

Abstract

33, alkylr fluoroalkyl.

IPC Classes  ?

• H01M 10/0567 - Liquid materials characterised by the additives
• H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodes; Lithium-ion batteries
• H01M 10/42 - Methods or arrangements for servicing or maintenance of secondary cells or secondary half-cells
• C07D 317/12 - Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
• C07D 317/16 - Radicals substituted by halogen atoms or nitro radicals
• C07D 317/42 - Halogen atoms or nitro radicals
• H01M 10/0568 - Liquid materials characterised by the solutes
• H01M 10/0569 - Liquid materials characterised by the solvents

Abstract

3166 alkyl which may be at least partially fluorinated and -OR group can be cis- or trans- to any other group X.

IPC Classes  ?

• H01M 10/0525 - Rocking-chair batteries, i.e. batteries with lithium insertion or intercalation in both electrodes; Lithium-ion batteries
• H01M 10/0567 - Liquid materials characterised by the additives
• H01M 10/0568 - Liquid materials characterised by the solutes
• H01M 10/0569 - Liquid materials characterised by the solvents
• H01M 10/42 - Methods or arrangements for servicing or maintenance of secondary cells or secondary half-cells

Abstract

A method of improving the stability of a pharmaceutical composition comprising (i) a propellant component and (ii) a drug component comprising at least one cannabinoid which is dissolved or suspended in the propellant is described. The method comprises using a propellant component comprising 1,1-difluoroethane (R- 152a).

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/06 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite

Abstract

A method for at least partially draining an operating system, which contains a working fluid (comprising carbon dioxide (R744) and a halogenated hydrocarbon). The method comprises transferring the working fluid to a target container, from the operating system, wherein the working fluid is contacted with an absorptive bed.

IPC Classes  ?

• F25B 45/00 - Arrangements for charging or discharging refrigerant
• B01D 53/02 - Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by adsorption, e.g. preparative gas chromatography
• B01D 53/96 - Regeneration, reactivation or recycling of reactants
• B01J 20/30 - Processes for preparing, regenerating or reactivating
• F25B 9/00 - Compression machines, plants or systems, in which the refrigerant is air or other gas of low boiling point

Abstract

A method for at least partially draining an operating system, which contains a working fluid (comprising carbon dioxide (R744) and a halogenated hydrocarbon). The method comprises transferring the working fluid to a target container, from the operating system, wherein the working fluid is contacted with an absorptive bed.

IPC Classes  ?

• F25B 9/00 - Compression machines, plants or systems, in which the refrigerant is air or other gas of low boiling point
• F25B 45/00 - Arrangements for charging or discharging refrigerant

Abstract

f—C≡CX; and (iii) recovering the (hydro)halocarbon.

IPC Classes  ?

• C07C 17/087 - Preparation of halogenated hydrocarbons by addition of hydrogen halides to unsaturated halogenated hydrocarbons
• C07C 17/20 - Preparation of halogenated hydrocarbons by replacement by halogens of halogen atoms by other halogen atoms
• C07C 17/25 - Preparation of halogenated hydrocarbons by splitting-off hydrogen halides from halogenated hydrocarbons
• C07C 17/38 - Separation; Purification; Stabilisation; Use of additives
• C07C 17/395 - Separation; Purification; Stabilisation; Use of additives by treatment giving rise to a chemical modification of at least one compound
• C07C 21/18 - Acyclic unsaturated compounds containing halogen atoms containing carbon-to-carbon double bonds containing fluorine
• C07C 19/08 - Acyclic saturated compounds containing halogen atoms containing fluorine

Abstract

A method of charging a container for use in a medication delivery apparatus wherein the propellant used comprises 1,1-difluoroethane (R-152a) is described.

IPC Classes  ?

• A61K 9/12 - Aerosols; Foams
• A61M 15/00 - Inhalators
• B65B 31/00 - Packaging articles or materials under special atmospheric or gaseous conditions; Adding propellants to aerosol containers
• B65B 31/04 - Evacuating, pressurising or gasifying filled containers or wrappers by means of nozzles through which air or other gas, e.g. an inert gas, is withdrawn or supplied
• B65D 83/14 - Containers or packages with special means for dispensing contents for delivery of liquid or semi-liquid contents by internal gaseous pressure, i.e. aerosol containers comprising propellant

Abstract

A method of charging a container for use in a medication delivery apparatus wherein the propellant used comprises 1,1-difluoroethane (R-152a) is described.

IPC Classes  ?

• A61K 9/12 - Aerosols; Foams
• A61M 15/00 - Inhalators
• B65B 31/00 - Packaging articles or materials under special atmospheric or gaseous conditions; Adding propellants to aerosol containers
• B65B 31/04 - Evacuating, pressurising or gasifying filled containers or wrappers by means of nozzles through which air or other gas, e.g. an inert gas, is withdrawn or supplied
• B65D 83/14 - Containers or packages with special means for dispensing contents for delivery of liquid or semi-liquid contents by internal gaseous pressure, i.e. aerosol containers comprising propellant

Abstract

A process for purifying 1,1-dif!uoroethane (H FA- 152a) contaminated with methyl chloride is described. The process comprises contacting the contaminated 1,1-dif!uoroetbane with a zeolite. Also described is a process for purifying 1,1-difluoroethane (HFA-152a) contaminated with methyl chloride and vinyl fluoride. This process comprises: contacting the contaminated 1,1-difluoroethane with a zeolite to remove methyl chloride and subjecting the 1,1- difluoroethane to a distillation process to remove vinyl fluoride. The purified 1,1-difluoroethane may also be subjected to a drying step to remove water in which the 1,1-difluoroethane is contacted with a drying agent.

IPC Classes  ?

• C07C 17/389 - Separation; Purification; Stabilisation; Use of additives by adsorption on solids
• C07C 19/08 - Acyclic saturated compounds containing halogen atoms containing fluorine

Abstract

A method for preparing a partially fluorinated alcohol, comprises reacting an epoxide: wherein R1, R2, R3 and R4 are independently selected from the group comprising H, F, Cl, Br, I, CF3, alkyl, fluoroalkyl, haloalkyl with a fluorinating agent.

IPC Classes  ?

• C07D 301/26 - Y being hydrogen
• C07D 303/08 - Compounds containing oxirane rings with hydrocarbon radicals, substituted by halogen atoms, nitro radicals or nitroso radicals

Abstract

A method for preparing a partially fluorinated alcohol, comprises reacting an epoxide: wherein R1, R2, R3and R433, alkyl, fluoroalkyl, haloalkyl with a fluorinating agent.

IPC Classes  ?

• C07D 301/26 - Y being hydrogen
• C07D 303/08 - Compounds containing oxirane rings with hydrocarbon radicals, substituted by halogen atoms, nitro radicals or nitroso radicals

Abstract

A pharmaceutical composition is described. The composition comprises: (i) a drug component comprising at least one salmeterol compound selected from salmeterol and the pharmaceutically acceptable derivatives thereof; and (ii) a propellant component comprising 1,1-difluoroethane (HFA-152a).

IPC Classes  ?

• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/12 - Aerosols; Foams
• A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

A pharmaceutical composition is described. The composition comprises: (i) a drug component comprising at least one salmeterol compound selected from salmeterol and the pharmaceutically acceptable derivatives thereof; and (ii) a propellant component comprising 1,1-difluoroethane (HFA-152a).

IPC Classes  ?

• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/12 - Aerosols; Foams
• A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61K 31/56 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

222, R-744). The present invention also provides a composition comprising R-1132a, R-32 and R-1234yf.

IPC Classes  ?

• C09K 5/04 - Materials undergoing a change of physical state when used the change of state being from liquid to vapour or vice-versa

Abstract

According to the present invention, there is provided a composition comprising 1,1- difluoroethylene (R-1132a), difluoromethane (R-32), 2,3,3,3-tetrafluoropropene (R-1234yf) and carbo dioxide (CO2, R-744). The invention also provides a composition R-1132a, R-32, R-1234yf and at least one compound selected from the group consisting of: pentafluoroethane (R-125), 1,1-difluoroethane (R-152a), 1,1,1,2-tetrafluoroethane (R-134a), trans-1,3,3,3-tetrafluoropropene (R-1234ze(E)) and 1,1,1,2,3,3,3-heptafluoropropane (R-227ea); optionally, the composition comprises at least one further compound selected from the group consisting of trifluoroethylene (R-1123), propane (R-290), propylene (R-1270), isobutane (R-600a) and carbon dioxide (CO2, R-744). The present invention also provides a composition comprising R-1132a, R-32 and R-1234yf.

IPC Classes  ?

• C09K 3/00 - Materials not provided for elsewhere
• B01D 11/02 - Solvent extraction of solids
• C09K 3/30 - Materials not provided for elsewhere for aerosols
• C09K 5/04 - Materials undergoing a change of physical state when used the change of state being from liquid to vapour or vice-versa
• C11D 7/50 - Solvents

Abstract

The invention provides a composition comprising (a) from about 6 to about 18 weight % R-1132a, (b) from about 5 to about 35 weight % R-32, and (c) from about 47 to about 89 weight % R-1234yf. The use of such a composition as a working fluid in a heat pump system of a vehicle, preferably an electric vehicle, is also provided.

IPC Classes  ?

• C09K 5/04 - Materials undergoing a change of physical state when used the change of state being from liquid to vapour or vice-versa
• F25B 1/00 - Compression machines, plants or systems with non-reversible cycle
• C08J 9/14 - Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof using blowing gases generated by a previously added blowing agent by a physical blowing agent organic
• C09K 3/00 - Materials not provided for elsewhere
• C09K 3/30 - Materials not provided for elsewhere for aerosols

Abstract

The invention provides a composition comprising (a) from about 6 to about 18 weight % R-1132a, (b) from about 5 to about 35 weight % R-32, and (c) from about 47 to about 89 weight % R-1234yf. The use of such a composition as a working fluid in a heat pump system of a vehicle, preferably an electric vehicle, is also provided.

IPC Classes  ?

• C09K 5/04 - Materials undergoing a change of physical state when used the change of state being from liquid to vapour or vice-versa

Abstract

2, polyalkylene glycol and polyolester; n is an integer from 2 to 250; m is an integer from 0 to 3; and p is an integer from 0 to 9.

IPC Classes  ?

• C10M 107/38 - Lubricating compositions characterised by the base-material being a macromolecular compound containing halogen
• C10M 171/00 - Lubricating compositions characterised by purely physical criteria, e.g. containing as base-material, thickener or additive, ingredients which are characterised exclusively by their numerically specified physical properties, i.e. containing ingredien
• C09K 5/04 - Materials undergoing a change of physical state when used the change of state being from liquid to vapour or vice-versa
• C09K 21/02 - Inorganic materials
• C09K 21/08 - Organic materials containing halogen
• C09K 21/10 - Organic materials containing nitrogen
• C09K 21/12 - Organic materials containing phosphorus
• C09K 21/14 - Macromolecular materials
• C10N 10/06 - Groups 3 or 13
• C10N 10/10 - Groups 5 or 15
• C10N 20/02 - Viscosity; Viscosity index
• C10N 20/00 - Specified physical properties of component of lubricating compositions
• C10N 30/08 - Resistance to extreme temperature
• C10N 40/30 - Refrigerator lubricant

Abstract

2CI (253fb) in the liquid phase in a first reactor, using HF as the fluorinating agent; and (b)(i) dehydrohalogenating 253fb to produce 1243zf in the vapour phase in the presence of a catalyst in a second reactor; or (b)(ii) dehydrohalogenating 253fb to produce 1243zf in a second reactor, wherein the reaction product comprising 253fb produced in step (a) has subjected to one or more purification steps before step (b). The present invention also provides an azeotropic or near-azeotropic composition comprising HF and 253fb.

IPC Classes  ?

• C07C 17/25 - Preparation of halogenated hydrocarbons by splitting-off hydrogen halides from halogenated hydrocarbons
• C07C 17/35 - Preparation of halogenated hydrocarbons by reactions not affecting the number of carbon or halogen atoms in the molecules
• C07C 17/07 - Preparation of halogenated hydrocarbons by addition of hydrogen halides
• C09K 5/04 - Materials undergoing a change of physical state when used the change of state being from liquid to vapour or vice-versa

Abstract

2, 1233xf), hydrogen chloride (HCl) and, optionally, air; and gas phase catalytic fluorination with hydrogen fluoride (HF) of the intermediate composition to produce a reactor product composition comprising 245cb, HF, HCl and air; wherein the process is carried out with a co-feed of air.

IPC Classes  ?

• C07C 17/20 - Preparation of halogenated hydrocarbons by replacement by halogens of halogen atoms by other halogen atoms
• B01J 23/06 - Catalysts comprising metals or metal oxides or hydroxides, not provided for in group of zinc, cadmium or mercury
• B01J 23/26 - Chromium
• C07C 17/25 - Preparation of halogenated hydrocarbons by splitting-off hydrogen halides from halogenated hydrocarbons
• C07C 19/08 - Acyclic saturated compounds containing halogen atoms containing fluorine
• C07C 21/18 - Acyclic unsaturated compounds containing halogen atoms containing carbon-to-carbon double bonds containing fluorine

Abstract

A compound of formula (I): wherein W is independently selected from the group consisting of H, F, Cl, Br, and I; X is independently selected from the group consisting of H, F, Cl, Br, and I; Y is independently selected from the group consisting of F, Cl, Br, and I; Z is independently selected from the group consisting of H, F, Cl, Br, and I; n is an integer from 1 to 8; and n′ is an integer from 1 to 12.

IPC Classes  ?

• C07C 69/63 - Halogen-containing esters of saturated acids
• C09K 5/04 - Materials undergoing a change of physical state when used the change of state being from liquid to vapour or vice-versa
• C10M 171/00 - Lubricating compositions characterised by purely physical criteria, e.g. containing as base-material, thickener or additive, ingredients which are characterised exclusively by their numerically specified physical properties, i.e. containing ingredien
• C10M 105/54 - Lubricating compositions characterised by the base-material being a non-macromolecular organic compound containing halogen containing carbon, hydrogen, halogen and oxygen
• C07C 67/14 - Preparation of carboxylic acid esters from carboxylic acid halides
• C10M 105/18 - Ethers, e.g. epoxides
• C10M 105/38 - Esters of polyhydroxy compounds
• C10N 10/06 - Groups 3 or 13
• C10N 10/10 - Groups 5 or 15
• C10N 20/00 - Specified physical properties of component of lubricating compositions
• C10N 30/08 - Resistance to extreme temperature
• C10N 40/30 - Refrigerator lubricant
• C10N 30/00 - Specified physical or chemical property which is improved by the additive characterising the lubricating composition, e.g. multifunctional additives